Feed / BHC

Bausch Health Companies Inc.

BHC

Healthcare · 6.08 -5.5% today

Isolated · not yet confirmedMarket checked 10 Sept, 15:35 GMT-4

Market read

Bausch Health Companies Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 17 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 9 directly disclosed connections are confirming.

Company-5.5% todayVolume comparison unavailable
Market group0 of 17 activeHealthcare & Consumer Brands · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • BHC's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if BHC's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Drug Manufacturers - Specialty & Generic

No new filing conclusion is available. 0 of 17 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 9 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • BHC's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 10, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations318
Usable filing statements209
Verified relationships9
Evidence supporting the case
  • Latest annual revenue changed +6.7% year over year.
  • Operating margin changed +1.6 percentage points in the latest annual period.
  • Net margin changed +2.0 percentage points in the latest annual period.
  • Operating cash flow covered net income at 8.92x in the latest annual period.
  • Demand and volume has repeated favorable evidence across 4 filings.
Evidence challenging the case

No qualifying adverse evidence was identified; that is not proof there is no downside.

Questions before a position
  • P/E is 41% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 9, 2026

6.16
6m+2.0%12m-14.1%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$8.4B+5.1%$-2.64+1.1%
2022-12-31$8.1B-3.7%$-0.62+0.9%
2023-12-31$8.8B+7.8%$-1.62+0.8%
2024-12-31$9.6B+9.9%$-0.13+0.8%
2025-12-31$10.3B+6.7%$0.42+1.9%

What management says matters

Persistent and emerging business drivers

Credit and interest ratesmixed · 4 filings
Due to the accounting treatment for the 2022 Secured Notes, interest expense in the Company’s financial statements will not be representative of the weighted average stated rate of interest.
10-Q · Apr 30, 2026
Demand and volumepositive · 4 filings
The increase is attributable to growth in our Bausch + Lomb, Salix, Solta Medical and International segments driven by: (i) improved net realized pricing, (ii) higher volumes, (iii) the favorable impact of foreign currencies, (iv) the impact of divestitures a…
10-K · Feb 19, 2026
Restructuring and cost reductionsmixed · 4 filings
Our effective income tax rate for the three months ended March 31, 2026 differs from the statutory Canadian income tax rate primarily due to: (i) the impairment to goodwill for which no tax benefit is recognized, (ii) the recording of valuation allowances on…
10-Q · Apr 30, 2026
Foreign exchangenegative · 3 filings
This change was primarily driven by: (i) transaction gains and losses on intercompany balances and third-party liabilities and (ii) gains and losses from foreign currency exchange contracts.
10-Q · Apr 30, 2026

Valuation discipline

Descriptive valuation snapshot

Price/sales 0.2× · EV/sales 2.1×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

6.08-5.5% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:35 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for BHC. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for BHC. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind BHC

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

CAHCardinal Health, Inc.supplierFeb 19, 2026

The Company has Distribution Services Agreements (“DSAs”) with several large wholesale customers such as McKesson Corporation, Cencora Inc., Cardinal Health, Inc.

CORCencora, Inc.supplierFeb 19, 2026

The Company has Distribution Services Agreements (“DSAs”) with several large wholesale customers such as McKesson Corporation, Cencora Inc., Cardinal Health, Inc.

Depended on by

COOThe Cooper Companies, Inc.competitorDec 5, 2025

Our largest competitors in the contact lens business, Johnson & Johnson Vision Care, Inc., Alcon Inc.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 6 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

BHC is currently a Follower in the organic co-movement group Healthcare & Consumer Brands. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for BHC; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.